MedTrace Logo

MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema

NCT04187443 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2025-09-29

No results posted yet for this study

Summary

This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema. Fifteen subjects with diabetic macular edema will be enrolled into each of three dose cohorts and will receive oral administration of MS-553 for 8 weeks.

Conditions

Interventions

DRUG

MS-553

MS-553

Sponsors & Collaborators

  • Fountain Medical Development Co., Ltd.

    collaborator INDUSTRY

  • Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Kai Zhang, MD · Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-02
Primary Completion
2026-10-30
Completion
2026-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04187443 on ClinicalTrials.gov